Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • pre-exposure prophylaxis

    - PMLiVE

    Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

    An estimated 1.2 million people in the US are currently living with the virus

    - PMLiVE

    Gilead Sciences and Kymera enter oncology partnership worth up to $750m

    The companies will focus on advancing Kymera’s oral molecular glue degrader programme

    - PMLiVE

    Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

    More than 100 people in the US were diagnosed with HIV every day in 2023

    - PMLiVE

    Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC

    Primary biliary cholangitis affects approximately 163,000 people in Europe

    - PMLiVE

    Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults

    The company gained access to the drug through its $4.3bn acquisition of CymaBay

    - PMLiVE

    Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

    Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

    - PMLiVE

    Gilead appoints Dietmar Berger as chief medical officer

    Berger most recently served as chief medical officer and global head of development at Sanofi

    - PMLiVE

    Gilead and AI-focused Genesis partner to develop small molecule therapies

    The companies will use Genesis’ AI platform to generate and optimise molecules for targets selected by Gilead

    - PMLiVE

    GSK’s ViiV shares positive head-to-head results for two-drug HIV regimen Dovato

    The phase 4 trial has been comparing Dovato against Gilead’s three-drug regimen, Biktarvy

    - PMLiVE

    MHRA approves first generic raltegravir medicines to treat HIV in adults and children

    More than 91,000 people in England were diagnosed with HIV and accessing care in 2022

    - PMLiVE

    Gilead shares positive phase 3 results for twice-yearly HIV PrEP drug in women

    Lenacapavir demonstrated 100% efficacy in protecting more than 2,000 women against the infection

    - PMLiVE

    Gilead’s investigational seladelpar shows promise in primary biliary cholangitis

    The company gained access to the candidate through its $4.3bn acquisition of CymaBay in March

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links